A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on @entity688 serum levels in @entity1 with XXXX .

@entity1 @entity32 @entity12131 @entity565 @entity56 @entity6410 @entity688 @entity5203 @entity2713
BACKGROUND: Levels of an immunoregulatory and anti-inflammatory cytokine @entity688 are reduced in asthmatic airways, potentially contributing to more intense @entity32 . @entity2713 has anti-inflammatory properties and the anti-inflammatory effects of @entity5203 and @entity6410 have been discussed. OBJECTIVE: The purpose of this study was to define the effect of treatment with @entity2713 , @entity5203 and @entity6410 on the serum level of @entity688 , eosinophil blood counts, eosinophil cationic response (ECP) and clinical parameters (symptom score, FEV1 and PC20H) in @entity1 with moderate @entity565 . METHODS: An 8-week, placebo-controlled and randomized, double-blind trial was carried out. The subjects were 91 @entity1 with moderate @entity12131 who were @entity56 to dust mite. @entity1 were randomly allocated to receive 400 microg @entity2713 (n = 19), 5 or 10 mg (according to age) @entity5203 (n = 18), 24 microg @entity6410 (n = 18) or placebo (n = 36). RESULTS: Seventy-nine @entity1 completed the study. After treatment with @entity2713 and @entity5203 the level of @entity688 in blood serum significantly increased, eosinophil blood counts and ECP levels significantly decreased and all clinical parameters improved; treatment with @entity6410 had no effect on @entity688 level, eosinophil blood counts in serum and bronchial hyper-reactivity; ECP level significantly decreased after treatment and @entity565 symptoms and FEV1 improved significantly. Mean @entity688 levels in serum before and after treatment with @entity2713 were 7.23 pg/mL with 95% CI, 6.74 -7.72% and 14.24 pg/mL with 95% CI, 11.6-16.88%, respectively (P < 0.001); with @entity5203 they were 6.59 pg/mL with 95% CI, 6.26-7.23% and 10.94 pg/mL with 95% CI, 8.24-12.65%, respectively (P < 0.002); with @entity6410 they were 7.06 pg/mL with 95% CI, 6.61-7.52% and 7.04 pg/mL with 95% CI, 6.15-7.93%. We found statistically significant correlations between serum level of @entity688 and serum level of ECP after treatment with @entity2713 and @entity5203 . CONCLUSION: This study demonstrates that one possible way by which @entity2713 and @entity5203 contribute to inhibition of @entity32 is by increasing @entity688 levels.
